

Julia R Trosman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5068681/publications.pdf>

Version: 2024-02-01

44
papers

884
citations

430874

18
h-index

477307

29
g-index

44
all docs

44
docs citations

44
times ranked

1264
citing authors

#	ARTICLE	IF	CITATIONS
1	The economic value of personalized medicine tests: what we know and what we need to know. <i>Genetics in Medicine</i> , 2014, 16, 251-257.	2.4	91
2	Barriers to the Use of Personalized Medicine in Breast Cancer. <i>Journal of Oncology Practice</i> , 2012, 8, e24-e31.	2.5	61
3	Telehealth in Oncology During the COVID-19 Outbreak: Bringing the House Call Back Virtually. <i>JCO Oncology Practice</i> , 2020, 16, 289-293.	2.9	56
4	Genomic Sequencing: Assessing The Health Care System, Policy, And Big-Data Implications. <i>Health Affairs</i> , 2014, 33, 1246-1253.	5.2	53
5	Coverage Policy Development for Personalized Medicine: Private Payer Perspectives on Developing Policy for the 21-Gene Assay. <i>Journal of Oncology Practice</i> , 2010, 6, 238-242.	2.5	51
6	Health Technology Assessment and Private Payers' Coverage of Personalized Medicine. <i>Journal of Oncology Practice</i> , 2011, 7, 18s-24s.	2.5	44
7	Payer coverage policies for multigene tests. <i>Nature Biotechnology</i> , 2017, 35, 614-617.	17.5	42
8	Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS). <i>Genetics in Medicine</i> , 2020, 22, 283-291.	2.4	41
9	Challenges of Coverage Policy Development for Next-Generation Tumor Sequencing Panels: Experts and Payers Weigh In. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 311-318.	4.9	39
10	Why do breast cancer programs fail to refer patients to genetic counseling upon obtaining family history?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1553-1553.	1.6	37
11	Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 219-228.	4.9	35
12	Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited. <i>Genetics in Medicine</i> , 2019, 21, 152-160.	2.4	29
13	Care for a Patient With Cancer As a Project: Management of Complex Task Interdependence in Cancer Care Delivery. <i>Journal of Oncology Practice</i> , 2016, 12, 1101-1113.	2.5	25
14	Availability and payer coverage of BRCA1/2 tests and gene panels. <i>Nature Biotechnology</i> , 2015, 33, 900-902.	17.5	22
15	Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 11-17.	4.9	21
16	A Standardized BCR-ABL Monitoring Test: Assessment of Potential Adoption Impacts In Healthcare In the United States. <i>Blood</i> , 2010, 116, 4754-4754.	1.4	21
17	Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. <i>Genetics in Medicine</i> , 2017, 19, 559-567.	2.4	19
18	From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. <i>Value in Health</i> , 2018, 21, 1062-1068.	0.3	19

#	ARTICLE	IF	CITATIONS
19	Biomarker Testing for Breast, Lung, and Gastroesophageal Cancers at NCI Designated Cancer Centers. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	18
20	“What Goes Around Comes Around”: Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. <i>Value in Health</i> , 2017, 20, 47-53.	0.3	18
21	Insurance coverage for genomic tests. <i>Science</i> , 2018, 360, 278-279.	12.6	18
22	Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. <i>Value in Health</i> , 2017, 20, 40-46.	0.3	17
23	Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2403.	7.4	17
24	Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. <i>Journal of Genetic Counseling</i> , 2022, 31, 130-139.	1.6	13
25	Radiology as the Point of Cancer Patient and Care Team Engagement: Applying the 4R Model at a Patient's Breast Cancer Care Initiation. <i>Journal of the American College of Radiology</i> , 2016, 13, 1579-1589.	1.8	12
26	Capacity building for assessing new technologies: approaches to examining personalized medicine in practice. <i>Personalized Medicine</i> , 2010, 7, 427-439.	1.5	10
27	Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. <i>Value in Health</i> , 2020, 23, 551-558.	0.3	9
28	What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of <i>HER2</i> / <i>Neu</i> testing in breast cancer. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 461-477.	1.4	7
29	US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER). <i>Genetics in Medicine</i> , 2022, 24, 238-244.	2.4	6
30	Health technology assessment and private payers' coverage of personalized medicine. <i>American Journal of Managed Care</i> , 2011, 17 Suppl 5 Developing, SP53-60.	1.1	6
31	Systematic Patient Navigation Strategies to Scale Breast Cancer Disparity Reduction by Improved Cancer Prevention and Care Delivery Processes. <i>JCO Oncology Practice</i> , 2020, 16, e1462-e1470.	2.9	5
32	Company Profile: Center for Business Models in Healthcare. <i>Personalized Medicine</i> , 2013, 10, 333-337.	1.5	4
33	New Medicare Coverage Policy for Next-Generation Tumor Sequencing: A Key Shift in Coverage Criteria With Broad Implications Beyond Medicare. <i>JCO Precision Oncology</i> , 2018, 2, 1-5.	3.0	3
34	Innovating Cancer Care Delivery: the Example of the 4R Oncology Model for Colorectal Cancer Patients. <i>Current Treatment Options in Oncology</i> , 2019, 20, 11.	3.0	3
35	What are NCI-designated cancer centers using for gastric and esophageal cancer <i>HER2</i> testing?. <i>Journal of Clinical Oncology</i> , 2013, 31, e15010-e15010.	1.6	3
36	Evaluation of the Novel 4R Oncology Care Planning Model in Breast Cancer: Impact on Patient Self-Management and Care Delivery in Safety-Net and Non-Safety-Net Centers. <i>JCO Oncology Practice</i> , 2021, 17, e1202-e1214.	2.9	2

#	ARTICLE	IF	CITATIONS
37	Biomarker testing methods in breast, gastric, and lung cancers: A benchmarking survey of NCI cancer centers.. Journal of Clinical Oncology, 2013, 31, e22093-e22093.	1.6	2
38	Abstract A38: Are breast cancer screening patients with family cancer history directed to genetic counseling/testing?. , 2011, , .		1
39	What are NCI-designated cancer centers using for breast cancer HER2 testing?. Journal of Clinical Oncology, 2013, 31, 626-626.	1.6	1
40	Are oncologists involved in cancer biomarker decisions at their institutions?. Journal of Clinical Oncology, 2013, 31, 6617-6617.	1.6	1
41	Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants. Journal of Community Genetics, 2021, , 1.	1.2	1
42	Assessing Breast Cancer Risks to Improve Care for an Increased-Risk Population within Eastern North Carolina. North Carolina Medical Journal, 2022, 83, 221-228.	0.2	1
43	4R COVID-19 Toolkit for Patient Self-Management of Mild or Moderate COVID-19 symptoms. SSRN Electronic Journal, 0, , .	0.4	0
44	BPI20-017: Innovating Patient-Facing Care Pathways in Breast Cancer Using the 4R model, 4R = Right Information / Care / Patient / Time. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, BPI20-017.	4.9	0